{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:35:02Z","timestamp":1785818102644,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.urology.2015.01.002","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T16:45:01Z","timestamp":1424450701000},"page":"786-790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder"],"prefix":"10.1016","volume":"85","author":[{"given":"Yoshihisa","family":"Matsukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokunori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momokazu","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2015.01.002_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2015.01.002_bib2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1464-410X.2009.08369.x","article-title":"The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS","volume":"103","author":"Sexton","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.01.002_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2006.05.045","article-title":"Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment","volume":"68","author":"Brubaker","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urology.2015.01.002_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1442-2042.2008.02177.x","article-title":"Clinical guidelines for overactive bladder","volume":"16","author":"Yamaguchi","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib7","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.01.002_bib8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/physrev.00038.2003","article-title":"Urinary bladder contraction and relaxation: physiology and pathophysiology","volume":"84","author":"Andersson","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1016\/j.urology.2015.01.002_bib9","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/sj.bjp.0706619","article-title":"a1-, a2- and \u03b2-adrenoceptors in the urinary bladder, urethra and prostate","volume":"147","author":"Michel","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.urology.2015.01.002_bib10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.bjp.0702358","article-title":"Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle","volume":"126","author":"Igawa","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.urology.2015.01.002_bib11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","article-title":"Evidence for \u03b23-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods","volume":"288","author":"Takeda","year":"1999","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.urology.2015.01.002_bib12","first-page":"680","article-title":"Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle","volume":"161","author":"Fujimura","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0090-4295(01)01635-1","article-title":"\u03b23-adrenoceptors in human detrusor muscle","volume":"59","author":"Yamaguchi","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2015.01.002_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomized, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50 mg once-daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.01.002_bib16","first-page":"1388","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","article-title":"Symptom assessment tool for overactive bladder syndrome\u2014overactive bladder symptom score","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urology.2015.01.002_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/nau.20389","article-title":"Correlations between the ICIQ-SF score and urodynamic findings","volume":"26","author":"Seckiner","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2015.01.002_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/nau.10066","article-title":"Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies","volume":"21","author":"Sch\u00e4fer","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2015.01.002_bib20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.01.002_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/nau.10130","article-title":"Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in\u00a0vitro","volume":"22","author":"Yamanishi","year":"2003","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2015.01.002_bib22","first-page":"1142","article-title":"Efficacy of the \u03b23-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat","volume":"166","author":"Woods","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00210-012-0814-3","article-title":"Effect of mirabegron, a novel \u03b23-adrenoceptor agonist, on bladder function during storage phase in rats","volume":"386","author":"Hatanaka","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.urology.2015.01.002_bib24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1447-0756.2010.01493.x","article-title":"Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome","volume":"37","author":"Hsiao","year":"2011","journal-title":"J\u00a0Obstet Gynaecol Res"},{"key":"10.1016\/j.urology.2015.01.002_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1442-2042.2010.02602.x","article-title":"Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder","volume":"17","author":"Tanaka","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib26","first-page":"1320","article-title":"Urodynamics and safety of the \u03b2\u2083-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.01.002_bib27","first-page":"114","article-title":"Factors that influence the incidence of detrusor instability in women","volume":"130","author":"Awad","year":"1983","journal-title":"J\u00a0Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429515000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429515000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:29:38Z","timestamp":1747686578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429515000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0090429515000205"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2015.01.002","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2015.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}